Zoetis Inc. $ZTS Shares Sold by OFI Invest Asset Management

OFI Invest Asset Management trimmed its position in Zoetis Inc. (NYSE:ZTS) by 14.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 268,273 shares of the company’s stock after selling 44,872 shares during the period. OFI Invest Asset Management’s holdings in Zoetis were worth $33,754,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of ZTS. Brighton Jones LLC boosted its holdings in Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after purchasing an additional 2,978 shares during the last quarter. Empowered Funds LLC lifted its holdings in shares of Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after acquiring an additional 657 shares during the last quarter. Intech Investment Management LLC lifted its holdings in shares of Zoetis by 17.2% in the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after acquiring an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC lifted its holdings in shares of Zoetis by 73.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after acquiring an additional 1,422 shares during the last quarter. Finally, Gamco Investors INC. ET AL lifted its holdings in shares of Zoetis by 33.1% in the 2nd quarter. Gamco Investors INC. ET AL now owns 15,690 shares of the company’s stock worth $2,447,000 after acquiring an additional 3,901 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

Zoetis stock opened at $119.66 on Thursday. The firm has a market cap of $50.51 billion, a PE ratio of 19.88, a price-to-earnings-growth ratio of 1.80 and a beta of 0.98. Zoetis Inc. has a 52-week low of $113.29 and a 52-week high of $172.23. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The company’s 50 day moving average is $122.39 and its two-hundred day moving average is $127.49.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same period in the prior year, the business earned $1.40 EPS. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ZTS. HSBC set a $140.00 price objective on shares of Zoetis in a report on Wednesday, December 10th. Leerink Partners restated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. William Blair restated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Finally, UBS Group set a $136.00 price objective on shares of Zoetis in a report on Thursday, January 29th. Six analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.